CN100467027C - Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品 - Google Patents

Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品 Download PDF

Info

Publication number
CN100467027C
CN100467027C CNB2003801031384A CN200380103138A CN100467027C CN 100467027 C CN100467027 C CN 100467027C CN B2003801031384 A CNB2003801031384 A CN B2003801031384A CN 200380103138 A CN200380103138 A CN 200380103138A CN 100467027 C CN100467027 C CN 100467027C
Authority
CN
China
Prior art keywords
quinazoline
chloro
base
group
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801031384A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711094A (zh
Inventor
A·巴格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1711094A publication Critical patent/CN1711094A/zh
Application granted granted Critical
Publication of CN100467027C publication Critical patent/CN100467027C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2003801031384A 2002-11-13 2003-11-07 Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品 Expired - Fee Related CN100467027C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226434.9 2002-11-13
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product

Publications (2)

Publication Number Publication Date
CN1711094A CN1711094A (zh) 2005-12-21
CN100467027C true CN100467027C (zh) 2009-03-11

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801031384A Expired - Fee Related CN100467027C (zh) 2002-11-13 2003-11-07 Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品

Country Status (16)

Country Link
US (1) US20060142297A1 (OSRAM)
EP (1) EP1562612B1 (OSRAM)
JP (1) JP2006508953A (OSRAM)
KR (1) KR20050074573A (OSRAM)
CN (1) CN100467027C (OSRAM)
AT (1) ATE456370T1 (OSRAM)
AU (1) AU2003279456B2 (OSRAM)
BR (1) BR0316170A (OSRAM)
CA (1) CA2504666A1 (OSRAM)
DE (1) DE60331162D1 (OSRAM)
ES (1) ES2338109T3 (OSRAM)
GB (1) GB0226434D0 (OSRAM)
NO (1) NO20052312L (OSRAM)
NZ (1) NZ539514A (OSRAM)
WO (1) WO2004043472A1 (OSRAM)
ZA (1) ZA200503805B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004041829A1 (en) 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057251A2 (en) * 2001-01-22 2002-07-25 Novartis Ag Process for preparing intermediates for the manufacture of discodermolide and discodermolide analogues

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
HUP0103640A3 (en) * 1998-09-25 2003-01-28 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
CA2383546A1 (en) * 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057251A2 (en) * 2001-01-22 2002-07-25 Novartis Ag Process for preparing intermediates for the manufacture of discodermolide and discodermolide analogues

Also Published As

Publication number Publication date
AU2003279456B2 (en) 2007-05-17
WO2004043472A1 (en) 2004-05-27
DE60331162D1 (de) 2010-03-18
ES2338109T3 (es) 2010-05-04
GB0226434D0 (en) 2002-12-18
EP1562612A1 (en) 2005-08-17
BR0316170A (pt) 2005-09-27
NO20052312L (no) 2005-06-06
ZA200503805B (en) 2006-09-27
CA2504666A1 (en) 2004-05-27
KR20050074573A (ko) 2005-07-18
US20060142297A1 (en) 2006-06-29
CN1711094A (zh) 2005-12-21
ATE456370T1 (de) 2010-02-15
EP1562612B1 (en) 2010-01-27
AU2003279456A1 (en) 2004-06-03
JP2006508953A (ja) 2006-03-16
NZ539514A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
CN100467027C (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN102612369B (zh) 抗肿瘤效果增强剂
CN1976906B (zh) 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物
ES2365223T3 (es) Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
AU2011296024B2 (en) Quinazoline compounds and methods of use thereof
ES2425068T3 (es) Compuestos de pirido[2,3-d]pirimidin-7-ona como inhibidores de PI3K-alfa para el tratamiento del cáncer
AU2010217929A1 (en) JAK kinase modulating quinazoline derivatives and methods of use thereof
IL152754A (en) Quinazoline derivatives, process for their preparation, pharmaceutical preparations containing them and their use as drugs and in the manufacture of drugs for the inhibition and / or treatment of diseases of solid tumors
JP2017537154A (ja) キナゾリン複素環式化合物、その製造方法及び癌を治療する上皮成長因子受容体阻害剤としての応用
CN103421005A (zh) 具有抗肿瘤活性的乙炔衍生物
CN101014590A (zh) 作为磷脂酰肌醇(pi)3－激酶抑制剂的2,4,6－三取代的嘧啶及其在癌症治疗中的用途
CN101218229A (zh) 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
EP2260026B1 (en) Quinazolinone derivatives as tubulin polymerization inhibitors
CN105218561A (zh) 稠合嘧啶环衍生物、其制备方法及应用
EP3601254B1 (en) Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors
CN107459519A (zh) 稠合嘧啶哌啶环衍生物及其制备方法和应用
MXPA05005119A (es) Producto de combinacion de inhibidor de la familia src de cinasas de tirosina de no receptor y gemcitabina.
CN118994163A (zh) 含有并环结构的化合物
CN101432276A (zh) 喹啉衍生物
CN101321768A (zh) 用作酪氨酸激酶抑制剂的4-苯胺基取代的喹唑啉衍生物
ZA200300569B (en) Quinazoline derivatives.
HK1195733B (en) Anti-tumor effect potentiator
HK1171185B (en) Anti-tumor effect potentiator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090311

Termination date: 20101107